Amgen Inc., one of the world’s leading biotechnology companies, priced an offering of US$24.0 billion aggregate principal amount of senior notes, consisting of eight tranches of senior notes. The proceeds of the notes will be used to fund Amgen’s acquisition of Horizon Therapeutics plc. The offering is the ninth largest corporate debt issuance and second […]
The post Latham & Watkins Represents Amgen in US$24 Billion Senior Notes Offering to Fund Acquisition of Horizon Therapeutics appeared first on Legal Desire.